What topics does this cannabis study cover?

This study covers research on: Addiction, Mental Health.

Where was this research published?

Published in Molecular psychiatry on April 29, 2026.

Addiction Mental Health

Early substance use creates path to multiple addictions

Polysubstance use disorders among US adults.

Molecular psychiatry • April 29, 2026 • Moderately Relevant

🤖

AI Summary

This large national study of over 92,000 US adults examined how multiple substance use disorders (SUDs) cluster together and how early substance initiation affects addiction severity. Researchers found that cannabis use disorder frequently co-occurs with other addictions, with 16.4% of adults with cannabis use disorder also meeting criteria for three or more other substance use disorders. The risk is even higher for those using harder drugs: 32-72% of people with methamphetamine, cocaine, or hallucinogen use disorders have multiple additional substance use disorders. These findings highlight that addiction is rarely isolated to a single substance.

The most striking discovery concerns the timing of first use. Adults who delayed substance initiation until age 21 or later showed 73-83% lower rates of polysubstance use disorders compared to those starting before age 18. Specifically, delaying cannabis use until ages 21-29 resulted in 21% fewer moderate-severe substance use disorders, while those who never used alcohol, cannabis, or nicotine at all had 45-62% lower disorder rates. This suggests that adolescent and young adult brains may be particularly vulnerable to addiction patterns, and postponing substance use substantially reduces long-term addiction severity.

These findings carry important implications for cannabis users and public health policy. The research doesn't argue that cannabis itself is uniquely addictive, but rather that early-onset substance use—regardless of the initial drug—sets a trajectory toward multiple addictions and greater overall morbidity and mortality. This underscores why preventing substance initiation before age 21 is critical for reducing the burden of addiction disorders in the population.

📄 Original Abstract

Polysubstance use disorders ( ≥ 2 substance use disorders (SUDs)) are associated with high morbidity and mortality. We analyzed data from 92,233 adult participants in the 2022-2023 US National Surveys on Drug Use and Health to estimate past-year prevalence of polysubstance use disorders and to examine their associations with age of substance use initiation. Multivariable logistic regression and Poisson regression were applied. Age- and sex-adjusted past-year prevalence of 2 SUDs was 19.2-44.9% (95% CIs=11.1-62.3%) among adults with any SUD. Age- and sex-adjusted past-year prevalence of ≥3 SUDs ranged from 16.4% (95% CI = 14.3-18.6%) among adults with cannabis use disorder, to 32.4-44.7% (95% CIs=29.1-51.3%) among those with opioid use disorder or prescription stimulant or tranquilizer/sedative use disorder, and up to 48.2-72.0% (95% CIs=39.4-81.7%) among those with methamphetamine, cocaine, or hallucinogen use disorder. Overall, compared to adults who initiated substance use before age 18, the number of SUDs was 73-83% lower for those who initiated at age ≥21 (range of incidence density ratios (IDRs)=0.17-0.27, 95% CIs=0.12-0.31). Specifically, compared with corresponding adult counterparts who initiated before age 18, the number of moderate-severe SUDs was 32% lower among those initiating alcohol at ages 21-29 (IDR = 0.68, 95% CI = 0.57-0.83), 21% lower among those initiating cannabis at ages 21-29 (IDR = 0.79, 95% CI = 0.69-0.90), and 45-62% lower (IDRs=0.38-0.55, 95% CIs=0.31-0.76) among adults who never initiated alcohol, cannabis, or nicotine use. The elevated prevalence of polysubstance use disorders associated with early initiation of substance use underscores the critical need for evidence-based strategies to prevent alcohol, cannabis, and nicotine consumption before age 21.

Paper Type

📄 Research

Publication

Journal: Molecular psychiatry
Published: April 29, 2026
PMID: 42056224
DOI: 10.1038/s41380-026-03618-z

Authors (10)

Beth Han National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, US.
Nora D Volkow National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, US.
Christopher M Jones Substance Abuse and Mental Health Services Administration, Rockville, MD, US.
Deborah Dowell Centers for Disease Control and Prevention, Atlanta, GA, US.
Grant Baldwin Centers for Disease Control and Prevention, Atlanta, GA, US.
+5 more authors